A 8-Week, Multicenter, Open-Label, Observational Study of Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder

AstraZeneca2 sites in 1 country1,000 target enrollmentJuly 2008

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Naturalistic
Sponsor: AstraZeneca
Enrollment: 1000
Locations: 2
Primary Endpoint: The change from the baseline to week 8 in Short Form of the Quality of Life Enjoyment and satisfaction Questionnaire (Q-LES-Q) score
Status: Completed
Last Updated: 17 years ago

The purpose of this study is to reassure the clinical study data on atypical antipsychotics effect on quality of life in Korean Bipolar patients.

Registry

clinicaltrials.gov

Start Date

July 2008

End Date

September 2008

Last Updated

17 years ago

Study Type

Observational

Sex

All

Sponsor

•The patient and the patient's legal representative (if any) must understand the nature of the study and must have given written consent.
•Meet DSM-IV-TR criteria for bipolar disorder (bipolar I disorder, bipolar II disorder) at the time of baseline.

•Serious or unstable, medical illness. Subjects with chronic illness may be included but must be stable and otherwise physically healthy on the basis of a physical examination, medical history.
•Known intolerance for or lack of response to atypical antipsychotics , as judged by the investigator.